5-chloro-2-(4-ethoxyphenyl)benzothiazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 5-chloro-2-(4-ethoxyphenyl)benzothiazole
• 英文别名: 5-Chloro-2-(4-ethoxyphenyl)benzo[d]thiazole；5-Chloro-2-(4-ethoxyphenyl)-1,3-benzothiazole；5-chloro-2-(4-ethoxyphenyl)-1,3-benzothiazole
• 化学式: C₁₅H₁₂ClNOS
• 分子量: 289.785
• InChiKey: AJKDFBCTGMJQSV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  50.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-乙氧基苯甲醛 、 2-氨基-4-氯苯硫醇 在 硝酸脲 作用下， 以 neat (no solvent, solid phase) 为溶剂， 以92%的产率得到5-chloro-2-(4-ethoxyphenyl)benzothiazole
  参考文献：
  名称：

  硝酸尿素催化的C-N和C-S键形成：5-氯-2-芳基苯并[d]噻唑衍生物的机械化学方法

  摘要：

  使用4-氯-2-氨基苯硫酚和芳香醛在硝酸尿素作为催化剂的情况下，使用机械化学砂轮技术合成了一系列取代的5-氯-2-芳基苯并[d]噻唑。该方案有效地在室温下在无金属条件下进行，并且可以在较短的反应时间（30-60 s）内以高收率或优异的收率获得所需的产物。所有合成的衍生物的结构通过光谱表征证实。设计的方案具有多个优点，例如环保，无溶剂，高收率，易于后处理和催化剂的可回收性。催化剂可重复使用至少四次，而活性没有明显损失。已经证明了一系列衍生物具有良好的官能团耐受性。

  DOI：

  10.1002/jhet.4224

文献信息

• Synthesis, and In Vitro and In Silico α-Glucosidase Inhibitory Studies of 5-Chloro-2-Aryl Benzo[d]thiazoles
  作者：Shazia Shah、Arshia、Kulsoom Javaid、Humaira Zafar、Khalid Mohammed Khan、Ruqaiya Khalil、Zaheer Ul-Haq、Shahnaz Perveen、M. Iqbal Choudhary

  DOI：10.1016/j.bioorg.2018.02.013

  日期：2018.8

  Twenty-five derivatives of 5-chloro-2-aryl benzo[d]thiazole (1-25) were synthesized and evaluated for their alpha-glucosidase (S. cerevisiae EC 3.2.1.20) inhibitory activity in vitro. Among them eight compounds showed potent activity with IC50 values between 22.1 +/- 0.9 and 136.2 +/- 5.7 mu M, when compared with standard acarbose (IC50 = 840 +/- 1.73 mu M). The most potent compounds 4, 9, and 10 showed IC50 values in the range of 22.1 +/- 0.9 to 25.6 +/- 1.5 mu M. Compounds 2, 5, 11, and 19 showed IC50 values within the range of 40.2 +/- 0.5 to 60.9 +/- 2.0 mu M. Compounds 1 and 3 were also found to be good inhibitors with IC50 values 136.2 +/- 5.7 and 104.8 +/- 9.9 lM, respectively. Their activities were compared with alpha-glucosidase inhibitor drug acarbose (standard) (IC50 = 840 +/- 1.73 mu M). The remaining compounds were inactive. Structure-activity relationships (SAR) have also been established. Kinetics studies indicated compounds 2, 3, 10, 19, and 25 to be non-competitive, while 1, 5, 9, and 11 as competitive inhibitors of alpha-glucosidase enzyme. All the active compounds (1-5, 9-11, and 19) were also found to be non-cytotoxic, in comparison to the standard drug i.e., doxorubicin (IC50 = 0.80 +/- 0.12 mu M) in MTT assay. Furthermore, molecular interactions of active compounds with the enzyme binding sites were predicted through molecular modeling studies. (C) 2018 Elsevier Inc. All rights reserved.